Oncology Xagena
Neuroendocrine tumors ( NETs ) comprise a heterogeneous family of neoplasms with a wide and complex spectrum of clinical behavior. They originate in a great diversity of tissues and are characterized ...
A study has compared the incidence of vascular thromboembolic events ( VTEs ) in patients with metastatic or unresectable urothelial carcinoma ( UC ) who were treated with Gemcitabine and Carboplatin ...
Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...
The outcomes and therapy of advanced urothelial carcinoma ( UC ) patients following discontinuation of PD-1/PD-L1 inhibitors are unclear. Researchers performed a retrospective analysis to examine ...
Trials of salvage therapy for advanced urothelial carcinoma have required prior Platinum-based therapy. This practice requires scrutiny since non-Platinum-based first-line therapy may be offered to Ci ...
Updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( MPDL3280A ) in people with locally advanced or metastatic urothelial carcinoma ...
Patients with metastatic urothelial carcinoma have few treatment options after failure of Platinum-based chemotherapy. In this trial, researchers have assessed treatment with Atezolizumab, an engineer ...
The results for Nivolumab ( Opdivo ) in the cohort of patients with metastatic urothelial cancer ( n=78 ), the most common type of bladder cancer, after Platinum-based therapy from CheckMate -032, a p ...
With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a study published in The American Journal of Pathology, resea ...
Updated results from the phase 3 KEYNOTE-045 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial carcinoma with disease progre ...
Nivolumab ( Opdivo ) has shown efficacy and acceptable safety in 2 open-label, multicenter studies ( CheckMate 032 and 275 ) and is approved for patients with metastatic urothelial carcinoma ( mUC ) ...
The results from an interim analysis of KEYNOTE-057, a phase 2 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bla ...
Activation of the PD-1 pathway has been implicated in resistance to BCG ( Bacillus Calmette–Guérin ) therapy. Pembrolizumab ( Keytruda ), a checkpoint inhibitor with significant activity in patients ...
Erdafitinib ( Balversa ) is a pan-FGFR kinase inhibitor for treatment of adults with metastatic urothelial carcinoma ( mUC ) with susceptible FGFR3/2 alterations and who progressed on 1 line or more o ...
Previous treatment with immune checkpoint inhibitor ( ICI ) is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for metastatic urothelial carcino ...
